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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of the informant based questionnaire IQCODE in a population free from dementia for the
delayed diagnosis of dementia.
Where data are available, we will describe the following.
1. The delayed verification diagnostic accuracy of IQCODE at various thresholds. We recognise that various thresholds or ’cut-off ’
scores have been used to define IQCODE screen positive states, and thus various ’subthreshold’ cut-points could be used to describe
individuals with cognitive problems not diagnostic of dementia. We have not pre-specified IQCODE cut-points of interest, rather we
will collect delayed verification test accuracy data for all cut-points described.
2. Effects of heterogeneity on the reported diagnostic accuracy of IQCODE for delayed verification dementia (see below).
Items of specific interest will include case-mix of population, IQCODE test format, time since index test and healthcare setting.
B A C K G R O U N D
Dementia is a substantial and growing public health concern
(Herbert 2013; Prince 2013). Depending on the case definition
employed, contemporary estimates of dementia prevalence in the
United States are in the range of 2.5 to 4.5 million individuals.
Changes in population demographics will be accompanied by in-
creases in global dementia incidence and prevalence. Although the
magnitude of the increase in prevalent dementia is debated, there
is no doubt that absolute numbers of older adults with demen-
tia will increase substantially in the short to medium term future
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(Ferri 2005).
A dementia diagnosis requires cognitive and functional decline.
A syndrome of cognitive problems beyond those expected for age
and education but not sufficient to impact on daily activities is
also recognised. This possible intermediate state between normal
cognitive ageing and pathological change is often labelled mild
cognitive impairment (MCI) or cognitive impairment no demen-
tia (CIND), although a variety of other terms are also used. For
consistency we use the term MCI throughout this review. A pro-
portion of individuals with MCI will develop a clinical dementia
state over time (estimated at 10% to 15% of MCI individuals an-
nually), while others will improve or remain stable. All definitions
of this ’pre-dementia’ state are based on key criteria of change in
cognition (subjective or reported by an informant) with objective
cognitive impairment but preserved functional ability.
A key element of effective management in dementia is early, ro-
bust diagnosis. Recent guidelines place emphasis on very early di-
agnosis to facilitate improved management and to allow informed
discussions and planning with patients and carers (Cordell 2013).
An early or unprompted assessment paradigm needs to distin-
guish early pathological change from normal states. Diagnosis of
early dementia or MCI is especially challenging. It is important to
recognise those who will progress to dementia as identification of
this group may allow for targeted intervention, however at present
there is no accepted method for determining prognosis.
The ideal would be expert, multidisciplinary assessment informed
by various supplementary investigations (neuropsychology, neu-
roimaging or other biomarkers). This approach is only really fea-
sible in a specialist memory service and is not suited to population
screening or case-finding.
In practice a two-stage process is often employed, with initial
’triage’ assessments that are suitable for use by non-specialists used
to select those patients who require further detailed assessment
(Boustani 2003). Various tools for initial cognitive screening have
been described (Brodaty 2002; Folstein 1975; Galvin 2005). Re-
gardless of the methods employed, there is scope for improvement
as observational work suggests that many patients with dementia
are not diagnosed (Chodosh 2004; Valcour 2000).
Screening assessment often takes the form of brief, direct cognitive
testing. Such an approach will only provide a ’snapshot’ of cogni-
tive function. However, a defining feature of dementia is cognitive
or neuropsychological change over time. Patients themselves may
struggle to make an objective assessment of personal change and so
an attractive approach is to question collateral sources with suffi-
cient knowledge of the patient. These informant based interviews
aim to retrospectively assess change in function.
An instrument that is prevalent in research and clinical practice,
particularly in Europe, is the Informant Questionnaire for Cogni-
tive Decline in the Elderly (IQCODE) with questionnaire based
interviews. This screening or triage tool is the focus of this review
(Jorm 2004).
Traditional screening tools for cognitive problems have defined
threshold scores that differentiate individuals likely to have demen-
tia from those with no dementia. As dementia is a progressive, neu-
rodegenerative disease, a population with cognitive problems will
have a range of test scores. Individuals with MCI, or indeed early
dementia, may have screening test scores that although not at a
threshold suggestive of dementia are still abnormal for age. It seems
plausible that a subthreshold score on a screening test such as IQ-
CODE could be predictive of future dementia states and so could
be used to target those individuals who may need follow up or
further investigation. This paradigm of using a screening test with
delayed verification of a dementia state is commonly employed in
studies of the diagnostic properties of dementia ’biomarkers’ but
can equally be applied to direct or informant based assessment
scales.
This review will focus on the use of the IQCODE in individuals
without a firm clinical dementia diagnosis and will assess the accu-
racy for delayed verification of a dementia diagnosis after prospec-
tive follow up.
Target condition being diagnosed
The target condition for this diagnostic test accuracy review is all
cause dementia (clinical diagnosis).
Dementia is a syndrome characterised by cognitive or neuropsy-
chological decline sufficient to interfere with usual functioning.
The neurodegeneration and clinical manifestations of dementia
are progressive.
Dementia remains a clinical diagnosis based on history from the
patient and suitable collateral sources, and direct examination in-
cluding cognitive assessment. There is no universally accepted,
ante-mortem, gold standard diagnostic strategy. We have chosen
expert clinical diagnosis as our gold standard (reference standard)
as we believe this is most in keeping with current diagnostic crite-
ria and best practice.
Dementia diagnosis can be made according to various interna-
tionally accepted diagnostic criteria, with exemplars being the
World Health Organization International Classification of Dis-
eases (ICD) and American Psychiatric Association Diagnostic and
Statistical Manual of Mental Disorders (DSM) for all cause de-
mentia and subtypes. The label of dementia encompasses varying
pathologies of which Alzheimer’s disease is the most common. Di-
agnostic criteria are available for specific dementia subtypes, that
is National Institute of Neurological and Communicative Disor-
ders and Stroke and the Alzheimer’sDisease and Related Disorders
Association (NINCDS-ADRDA) criteria for Alzheimer’s demen-
tia (McKhann 1984; McKhann 2011); McKeith criteria for Lewy
Body dementia (McKeith 2005); Lund criteria for frontotemporal
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dementias (McKhann 2001); and theNINDS-AIREN criteria for
vascular dementia (Roman 1993).
We are examining delayed verification of dementia and so will de-
scribe the properties of a standard screening tool (the IQCODE)
for detection of problems earlier in the disease journey than frank
dementia. A proportion of participants included in relevant stud-
ies are likely to haveMCI, that is cognitive problems beyond those
expected for age and education but not sufficient to impact on
daily activities. The usual research definition of MCI is that de-
scribed by Petersen (Peterson 2004); and various subtypes have
been proposed within the rubric of MCI. We will collate infor-
mation on MCI described using any validated criteria, however
the focus of the review is not IQCODE for the contemporaneous
diagnosis of MCI but rather IQCODE for a future diagnosis of
dementia. These two constructs are related but not synonymous as
only a proportion of individuals with MCI will develop dementia.
Index test(s)
Our index test will be the Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE) (Jorm 1988).
The IQCODE was originally described as a 26-item informant
questionnaire that seeks to retrospectively ascertain change in cog-
nitive and functional performance over a 10-year time period. IQ-
CODE is designed as a brief screen for potential dementia, usually
administered as a questionnaire given to the relevant proxy. For
each item the chosen proxy scores change on a five-point ordi-
nal hierarchical scale, with responses ranging from 1: ’has become
much better’ to 5: ’has become much worse’. This gives a sum-
score of 26 to 130 that can be averaged by the total number of
completed items to give a final score of 1.0 to 5.0, where higher
scores indicate greater decline.
First described in 1989, use of the IQCODE is prevalent in both
clinical practice and research. A literature describing the proper-
ties of IQCODE is available including studies of non-English IQ-
CODE translations, studies in specific patient populations and
modifications to the original 26-item direct informant interview
(Jorm 2004). Versions of the IQCODE have been produced in
other languages includingChinese,Dutch, Finnish, French,Cana-
dian French, German, Italian, Japanese, Korean, Norwegian, Pol-
ish, Spanish andThai (www.anu.edu.au/iqcode/). A shortened 16-
item version is also available; this modified IQCODE is com-
mon in clinical practice and has been recommended as the pre-
ferred IQCODE format (Jorm 2004). Further modifications to
the IQCODE are described including fewer items and assessment
over shorter time periods. Our analysis will include all versions
of IQCODE but results for original and modified scales will not
be pooled. In this review the term ’IQCODE’ will refer to the
original 26-item English language questionnaire as described by
Jorm. Other versions of IQCODE will be described according to
number of items and administration language (that is a 16-item
IQCODE for Spanish speakers will be described as ’IQCODE-
16 Spanish’).
In the original IQCODE development and validation work nor-
mative data were described, with a total score of > 93 or an average
score of > 3.31 indicative of cognitive impairment (Jorm 2004).
There is no consensus on the optimal threshold and certainly no
guidance on the use of subthreshold IQCODE scores for delayed
verification. In setting thresholds for any diagnostic test there is
a trade-off between sensitivity and specificity with the preferred
values partly determined by the purpose of the test.
Clinical pathway
Dementia develops over a trajectory of several years and screening
tests may be performed at different stages in the dementia path-
way. In this review we will consider any use of IQCODE as an
initial assessment for cognitive decline and we will not limit stud-
ies to a particular healthcare setting. We have operationalised the
various settings where the IQCODE may be used as secondary
care, primary care and community.
In secondary care settings, individuals will have been referred for
expert input but not exclusively due to memory complaints. Op-
portunistic screening of adults presenting as unscheduled admis-
sions to hospitals would be an exemplar secondary care pathway.
The rubric of secondary care also includes those individuals re-
ferred to dementia and memory specific services. This population
will have a high prevalence of cognitive disorders and mimics.
More individuals will have had a greater degree of prior cognitive
assessment than in other settings but cognitive testing is not always
performed prior to memory service referral (Menon 2011).
In the general practice and primary care setting, the individual self
presents to a non-specialist service because of subjective memory
complaints. Previous cognitive testing is unlikely but prevalence
will be reasonable high. Using IQCODE in this setting could be
described as ’triage’ or ’case-finding’. In the community setting,
the cohort is largely unselected and the approach may be described
as ’population screening’.
The IQCODE is not a diagnostic tool and the role of IQCODE in
clinical practice is identifying those whomay need further detailed
assessment or follow up.
Alternative test(s)
Several other dementia screening and assessment tools have been
described, for example Folstein’s mini-mental state examination
(Folstein 1975). These performance based measures for cognitive
screening all rely on comparing single or multidomain cognitive
testing against population-specific normative data.
Other informant interviews are also available. For example, the
AD-8 is an eight-question tool requiring dichotomous responses
(yes or no) and testing for perceived changes in memory, problem
solving, orientation and daily activities (Galvin 2005).
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For this review we will focus on papers that describe IQCODE di-
agnostic properties, we will not consider other cognitive screening
or assessment tools. Our IQCODE diagnostic test accuracy stud-
ies form part of a larger body of work by the Cochrane Dementia
and Cognitive Improvement Group (Quinn 2014) describing test
properties of all commonly used assessment tools (Appendix 1).
Rationale
There is no consensus on the optimal initial assessment for demen-
tia and choice is currently dictated by experience with a particular
instrument, time constraints and training. A better understanding
of the diagnostic properties of various strategies would allow for an
informed approach to testing. Critical evaluation of the evidence
base for screening tests or other diagnostic markers is of major im-
portance. Without a robust synthesis of the available information
there is the risk that future research, clinical practice and policy
will be built on erroneous assumptions about diagnostic validity.
This review will form part of a body of work describing the diag-
nostic properties of commonly used dementia tools. At present we
are conducting single test reviews andmeta-analyses. However, the
intention is to then collate these data by performing an overview,
allowing comparison of various test strategies.
O B J E C T I V E S
To determine the diagnostic accuracy of the informant based ques-
tionnaire IQCODE in a population free from dementia for the
delayed diagnosis of dementia.
Secondary objectives
Where data are available, we will describe the following.
1. The delayed verification diagnostic accuracy of IQCODE at
various thresholds. We recognise that various thresholds or ’cut-
off ’ scores have been used to define IQCODE screen positive
states, and thus various ’subthreshold’ cut-points could be used
to describe individuals with cognitive problems not diagnostic
of dementia. We have not pre-specified IQCODE cut-points of
interest, rather we will collect delayed verification test accuracy
data for all cut-points described.
2. Effects of heterogeneity on the reported diagnostic accuracy of
IQCODE for delayed verification dementia (see below).
Items of specific interest will include case-mix of population, IQ-
CODE test format, time since index test and healthcare setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
In this review we are looking at the properties of IQCODE for
diagnosis of the dementia state on prospective follow up, that is
investigating whether a subthreshold score on IQCODE in a pop-
ulation free of dementia at baseline assessment is associated with
development of dementia over a period of follow up. The impli-
cation is that at the time of testing the individual had a cognitive
problem sufficient to be picked up on screening but not yet meet-
ing dementia diagnostic criteria. We will describe this paradigm as
’delayed verification’ diagnostic test accuracy. IQCODE for con-
temporaneous diagnosis of dementia is covered by other Cochrane
reviews.
We anticipate that the majority of studies will be performed in
secondary care settings. We will include test studies performed
in other healthcare settings and classify these as: primary care or
community.
Case-control studies are known to potentially overestimate prop-
erties of a test and such studies will not be included.
Case studies or samples with very small numbers (for the purposes
of this review chosen as 10 participants) will not be included but
will be described in the table of excluded studies.
There may be cases where settings are mixed, for example a pop-
ulation study ’enriched’ with additional cases from primary care.
We will consider separate data for patients from each setting, if
available. If these data are not available we will treat these studies
as case-control studies and not include them in this review.
Participants
All adults (aged over 18 years) and with no formal diagnosis of
dementia will be eligible.
We have not predefined exclusion criteria relating to the case-mix
of the population studied but will assess this aspect of the study
as part of our assessment of heterogeneity. Where there is concern
that the participants are not representative, this will be explored
at study level using the risk of bias assessment framework outlined
below.
Index tests
Studies must include (not necessarily exclusively) IQCODE used
as an informant questionnaire for delayed verification.
IQCODE has been translated into various languages to allow
international administration. The properties of a translated IQ-
CODE in a cohort of non-English speakers may differ from prop-
erties of the original English language questionnaire. We will col-
lect data on the principle language used for IQCODE assessment.
For this review we will not consider other cognitive screening or
assessment tools. Where a paper describes the IQCODE with an
4Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of
healthcare settings (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in-study comparison against another screening tool, we will in-
clude the IQCODE data only. Where IQCODE is used in com-
bination with another cognitive screening tool we will include the
IQCODE data only.
Target conditions
Any clinical diagnosis of all cause (unspecified) dementia will be
included. Defining a particular dementia subtype is not required
although where available these data will be recorded.
Reference standards
Our reference standard will be clinical diagnosis of dementia. We
recognise that clinical diagnosis itself has a degree of variability
but this is not unique to dementia studies and does not invalidate
the basic diagnostic test accuracy approach.
The primary analysis will be for clinical diagnosis to include all
cause (unspecified) dementia, using any recognised diagnostic cri-
teria (for example ICD-10, DSM-IV). Dementia diagnosis may
specify a pathological subtype and all common dementia sub-
types will be included (examples are NINCDS-ADRDA, Lund-
Manchester, McKeith, NINCDS-AIREN). We have not defined
preferred diagnostic criteria for rarer forms of dementia (for exam-
ple alcohol related, HIV related, prion disease related) and these
will be considered under our rubric of ’all cause’ dementia and not
separately.
Clinicians may use imaging, pathology or other data to aid diag-
nosis, however diagnosis based only on these data without a cor-
responding clinical assessment will not be included. We recognise
that different iterations of diagnostic criteria may not be directly
comparable and that diagnosismay vary with the degree ormanner
in which the criteria have been operationalised (for example indi-
vidual clinician versus algorithm versus consensus determination);
data on the method and application of dementia diagnosis will be
collected for each study and potential effects will be explored as
part of our assessment of heterogeneity. Use of other (brief ) direct
performance tests in isolation will not be an acceptable method
for diagnosis.
We recognise that dementia diagnosis often comprises a degree of
informant assessment. Thus there is potential for incorporation
bias. We will explore the potential effects of this bias through our
risk of bias assessment.
Search methods for identification of studies
We will use a variety of information sources to ensure all relevant
studies are included. Terms for electronic database searching will
be devised in conjunction with the team at the Cochrane Demen-
tia and Cognitive Improvement Group. As this IQCODE review
forms part of a suite of reviews looking at informant scales we
have created a comprehensive search strategy designed to pick up
all cognitive assessment scales, we will complement this generic
search with searches specific to IQCODE terminology.
Electronic searches
We will search the specialised register of the Cochrane Demen-
tia and Cognitive Improvement Group, ALOIS (which includes
both intervention and diagnostic accuracy studies), MEDLINE
(OvidSP), EMBASE (OvidSP), BIOSIS (ISI Web of Knowl-
edge), Science Citation Index (ISIWeb of Knowledge), PsycINFO
(OvidSP), CINAHL (EBSCOhost) and LILACS (BIREME). See
Appendix 2 and Appendix 3 for the strategy we will run in MED-
LINE (OvidSP) along with a narrative describing how the strategy
was developed and validated. Similarly structured search strategies
will be designed using search terms appropriate for each database.
MeSH terms and other controlled vocabulary will be used where
appropriate.
We will also search sources specific to diagnostic accuracy or to
systematic reviews:
• MEDION database (Meta-analyses van Diagnostisch
Onderzoek at www.mediondatabase.nl);
• DARE (Database of Abstracts of Reviews of Effects at
www.york.ac.uk/inst/crd/crddatabases.html);
• HTA Database (Health Technology Assessments Database
in The Cochrane Library);
• ARIF database (Aggressive Research Intelligence Facility at
www.arif.bham.ac.uk).
No language or date restrictions will be applied to the electronic
searches. Translation services will be used as necessary.
Initial searches will be run by the Cochrane Dementia and Cog-
nitive Impairment Group Search Co-ordinator.
Searching other resources
Grey literature and proceedings: chosen electronic databases in-
clude assessments of conference proceedings.We will aim to access
theses or PhD abstracts from institutions known to be involved in
prospective dementia studies.
Handsearching: wewill not performhandsearching as there is little
published evidence of the benefits of handsearching for diagnostic
studies (Glanville 2012) .
Reference lists: we will check the reference lists of all relevant
studies and reviews in the field for further possible titles and the
process will be repeated until no new titles are found (Greenhalgh
1997).
Correspondence: we will contact research groups who have pub-
lished or are conducting work on IQCODE for dementia diagno-
sis, informed by results of the initial search.
Relevant studies will be used in PubMed to search for additional
studieswith the related article feature. Key studieswill be examined
in citation databases such as Science Citation Index and Scopus
to ascertain any further relevant studies.
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Data collection and analysis
Selection of studies
Two review authors will independently screen all titles generated
by the electronic database searches for relevance. Abstracts of se-
lected titles will be reviewed by the two review authors and all po-
tentially eligible studies will be selected for full paper review. Two
review authors will independently assess full manuscripts against
the inclusion criteria. Disagreement will be resolved by discussion
or by involving an arbitrator if necessary.
Where a studymay include useable data but these are not presented
in the published manuscript, we will contact the authors directly
to request further information. If the same data are presented in
more than one paper we will include the primary paper only.
The study selection process will be detailed in a PRISMA flow
diagram.
Data extraction and management
Data will be extracted to a study-specific pro forma that includes
clinical and demographic details of the participants, details of the
setting, details of IQCODE administration, and details of the
dementia diagnosis process.
Test accuracy data will be extracted to a standard two by two table.
Data extraction will be performed independently by two blinded
review authors. Disagreement in data extraction will be resolved
by discussion, with the use of an arbitrator if necessary.
For each included paper, the flow of patients (numbers recruited,
included, assessed) will be detailed in a flow diagram.
Assessment of methodological quality
As well as describing test accuracy, an important goal of the di-
agnostic test accuracy (DTA) process is to improve study design
and reporting in dementia diagnostic studies. For this reason we
will assess methodological and reporting quality using two com-
plementary processes.
Quality of study reporting will be assessed using the STARD
checklist (Bossuyt 2003) (Appendix 4). If it becomes available dur-
ing the course of the review we will use the proposed dementia-
specific extension to the STARD tool, STARDdem (http://stard-
dem.org/). STARD data will be tabulated and presented as an ap-
pendix to the review.
We will assess the methodological quality of each study us-
ing the QUADAS-2 tool (http://www.bris.ac.uk/quadas/quadas-
2) (Appendix 5). This tool incorporates domains specific to patient
selection, index test, reference standard and patient flow. Each do-
main is assessed for risk of bias and the first three domains are
also assessed for applicability. Certain key areas that are important
for quality assessment are participant selection, blinding and miss-
ing data. Following a group meeting of review authors we created
guidance for the application of QUADAS-2 to dementia screen-
ing assessments, specifically developing anchoring statements for
QUADAS based assessment that are suited to dementia test ac-
curacy studies. This QUADAS guidance was created through a
multidisciplinary working group and has been extensively piloted
(Davis 2013). The process and resulting statements for assessment
are described (Appendix 6).
QUADAS-2datawill not be used to forma summary quality score,
rather there will be a narrative summary describing the numbers
of studies that found high, low or unclear risk of bias or concerns
regarding applicability with corresponding tabular and graphical
displays.
Both assessments will be performed by paired independent raters
who are blinded to each other’s scores. Disagreement will be re-
solved by further review and discussion with recourse to a third
party arbitrator where necessary.
Statistical analysis and data synthesis
We are interested in test accuracy of IQCODE for the delayed
diagnosis of dementia using a dichotomous variable, ’dementia’ or
’no dementia’. Thus, wewill apply the currentDTA framework for
analysis of a single test and fit the extracted data to a standard two
by two data table showing binary test results cross-classified with
the binary reference standard. This process will be repeated for
each IQCODE threshold score described in the source papers. We
will repeat the process for each assessment if the reference standard
is assessed at more than one follow up, as well as exploring the
effect of time since index test in our assessment of heterogeneity.
We will use RevMan 5 to calculate sensitivity, specificity and 95%
confidence intervals (CIs) from the two by two tables abstracted
from the included studies. We will present individual study results
graphically by plotting estimates of sensitivities and specificities as
forest plots and in receiver operating characteristic (ROC) space.
To allow for pooled analysis, we will use software additional to
RevMan (SAS release 9.1). As we expect a common threshold,
we will use the bivariate approach in the first instance. We will
describe summary metrics of sensitivity, specificity and positive
and negative likelihood ratios all with corresponding 95% CIs. If
data allow we will use the HSROC method to explore differing
thresholds across studies.
We plan analysis across all studies; this will be for information
only and we will be cautious in how we interpret these data. Final
decisions on whether pooling data for meta-analysis is appropriate
will be made by review author consensus.
The ’delayed verification’ nature of the included studies adds a
further level of complexity as a proportion of individuals recruited
at baseline may be ’lost’ to subsequent review. In the first instance
we will apply the usual DTA framework ignoring any censoring
that might have occurred. We acknowledge that such a reduction
in the data may represent a significant oversimplification. We will
therefore adopt an intention to diagnose (ITD) approach if data
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allow. As a sensitivity analysis wewill present what the result would
be if all dropouts would have developed dementia and if all drop-
outs would not have developed dementia. We may also need to
assume that the proportion of positive and negative test results is
the same in the unknown as with the known participants in order
to do this.
Investigations of heterogeneity
Heterogeneity is expected in DTA reviews and ’traditional’ mea-
sures of heterogeneity that are used in meta-analysis are not ap-
propriate to DTA reviews.
We will include IQCODE studies that span various settings. We
will offer a narrative review of all studies. We will perform pooled
analysis across all studies for information but primary analyses will
be restricted to the various predefined healthcare settings.
The properties of a tool describe the behaviour of the instrument
under particular circumstances. Thus, for our assessment of po-
tential sources of heterogeneity (where data allow) we will collect
data on the following.
1. Included patients (age and case mix).
In the first instance we will explore age, taking age over 65 years
as a reference point. We suspect that the majority of included
participants in eligible studieswill be aged over 65 years. IQCODE
may have different properties in younger cohorts and so we will
look at age ranges within studies, and studies that have greater
than 20% of included participants younger than 65 years will be
graded as potentially unrepresentative and analysed separately.
We anticipate that most studies will be of unselected adults, how-
ever if the study if of a specific population, for example stroke
survivors, these data will be pooled and analysed separately.
2. Clinical criteria used to reach dementia diagnosis.
We will record the classification used (for example ICD-10, DSM-
IV) and the methodology used to reach dementia diagnosis (for
example individual assessment, group (consensus) assessment).
3. Technical features of the testing strategy.
Our focus will be the language of assessment. In the first instance
we will classify the assessments as English language and non-En-
glish language tests. Summary estimates will be compared for sub-
groups of interest: all language IQCODE and then English lan-
guage IQCODE versus non-English language IQCODE.
4. Factors specific to the delayed verification analysis.
Wewill assess test accuracy at various follow-up time points if avail-
able. We will record any interventions administered during follow
up that may influence the outcome (for example cholinesterase
inhibitors).
Sensitivity analyses
Where appropriate (that is if not already explored in our analyses
of heterogeneity), and as data allow, we will explore the sensitivity
of any summary accuracy estimates to aspects of study quality such
as nature of blinding and loss to follow up guided by the anchoring
statements developed in our QUADAS-2 exercise. Primary analy-
sis will include all eligible studies, sensitivity analysis will exclude
studies of low quality (high likelihood of bias) to determine if the
results are influenced by inclusion of the lower quality studies. Due
to the potential for bias, we have pre-specified that case-control
data will not be included.
Assessment of reporting bias
Reporting bias will not be investigated because of current uncer-
tainty about how it operates in test accuracy studies and in the
interpretation of existing analytical tools such as funnel plot.
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A P P E N D I C E S
Appendix 1. Commonly used cognitive assessment or screening tools
TEST Cochrane DTA review in process
Mini-mental state examination (MMSE) YES
GPcog YES
Minicog YES
Memory Impairment Screen (MIS) Still available
Abbreviated mental testing Still available
Clock drawing tests (CDT) Still available
Montreal Cognitive Assessment (MoCA) YES
IQCODE (informant interview) YES
For each test, the planned review will encompass diagnostic test accuracy in community; primary and secondary care settings. As well
as standard diagnosis, where applicable reviews will also describe delayed verification design trials.
Appendix 2. Search strategy for use with MEDLINE electronic database
MEDLINE In-process and other non-indexed citations and
MEDLINE 1950 to present (OvidSP)
1. IQCODE.ti,ab.
2. “informant questionnaire on cognitive decline”.ti,ab.
3. “Informant Questionnaire for Cognitive Decline in the El-
derly”.ti,ab
4. (“informant* questionnair*” adj3 (dement* or screening)).ti,ab
5. “informant* questionnair*”.ti,ab. AND exp *Dementia/
6. “screening test*”.ti,ab.
7. (dement* or alzheimer* or “cognit* impair*”).ti,ab.
8. exp Dementia/
9. or/6,7
10. 5 AND 8
11. or/1-5
12. or/10,11
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Appendix 3. Search strategy (MEDLINE OvidSP) run for specialised register (ALOIS)
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MEDLINE In-process and other non-indexed citations and
MEDLINE 1950 to present (OvidSP)
1. “word recall”.ti,ab.
2. “7-minute screen”.ti,ab.
3. “6 item cognitive impairment test”.ti,ab.
4. “6 CIT”.ti,ab.
5. “AB cognitive screen”.ti,ab.
6. “abbreviated mental test”.ti,ab.
7. “ADAS-cog”.ti,ab.
8. AD8.ti,ab.
9. “inform* interview”.ti,ab.
10. “animal fluency test”.ti,ab.
11. “brief alzheimer* screen”.ti,ab.
12. “brief cognitive scale”.ti,ab.
13. “clinical dementia rating scale”.ti,ab.
14. “clinical dementia test”.ti,ab.
15. “community screening interview for dementia”.ti,ab.
16. “cognitive abilities screening instrument”.ti,ab.
17. “cognitive assessment screening test”.ti,ab.
18. “cognitive capacity screening examination”.ti,ab.
19. “clock drawing test”.ti,ab.
20. “deterioration cognitive observee”.ti,ab.
21. “Dem Tect”.ti,ab.
22. “fuld object memory evaluation”.ti,ab.
23. “IQCODE”.ti,ab.
24. “mattis dementia rating scale”.ti,ab.
25. “memory impairment screen”.ti,ab.
26. “minnesota cognitive acuity screen”.ti,ab.
27. “mini-cog”.ti,ab.
28. “mini-mental state exam*”.ti,ab.
29. “mmse”.ti,ab.
30. “modified mini-mental state exam”.ti,ab.
31. “3MS”.ti,ab.
32. “neurobehavioural cognitive status exam*”.ti,ab.
33. “cognistat”.ti,ab.
34. “quick cognitive screening test”.ti,ab.
35. “QCST”.ti,ab.
36. “rapid dementia screening test”.ti,ab.
37. “RDST”.ti,ab.
38. “repeatable battery for the assessment of neuropsychological
status”.ti,ab
39. “RBANS”.ti,ab.
40. “rowland universal dementia assessment scale”.ti,ab.
41. “rudas”.ti,ab.
42. “self-administered gerocognitive exam*”.ti,ab.
43. (“self-administered” and “SAGE”).ti,ab.
44. “self-administered computerized screening test for dementia”.
ti,ab
45. “short and sweet screening instrument”.ti,ab.
46. “sassi”.ti,ab.
47. “short cognitive performance test”.ti,ab.
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48. “syndrome kurztest”.ti,ab.
49. “six item screener”.ti,ab.
50. “short memory questionnaire”.ti,ab.
51. (“short memory questionnaire” and “SMQ”).ti,ab.
52. “short orientation memory concentration test”.ti,ab.
53. “s-omc”.ti,ab.
54. “short blessed test”.ti,ab.
55. “short portable mental status questionnaire”.ti,ab.
56. “spmsq”.ti,ab.
57. “short test of mental status”.ti,ab.
58. “telephone interview of cognitive status modified”.ti,ab
59. “tics-m”.ti,ab.
60. “trail making test”.ti,ab.
61. “verbal fluency categories”.ti,ab.
62. “WORLD test”.ti,ab.
63. “general practitioner assessment of cognition”.ti,ab.
64. “GPCOG”.ti,ab.
65. “Hopkins verbal learning test”.ti,ab.
66. “HVLT”.ti,ab.
67. “time and change test”.ti,ab.
68. “modified world test”.ti,ab.
69. “symptoms of dementia screener”.ti,ab.
70. “dementia questionnaire”.ti,ab.
71. “7MS”.ti,ab.
72. (“concord informant dementia scale” or CIDS).ti,ab.
73. (SAPH or “dementia screening and perceived harm*”).ti,ab
74. or/1-73
75. exp Dementia/
76. Delirium, Dementia, Amnestic, Cognitive Disorders/
77. dement*.ti,ab.
78. alzheimer*.ti,ab.
79. AD.ti,ab.
80. (“lewy bod*” or DLB or LBD).ti,ab.
81. “cognit* impair*”.ti,ab.
82. (cognit* adj4 (disorder* or declin* or fail* or function*)).ti,ab
83. (memory adj3 (complain* or declin* or function*)).ti,ab.
84. or/75-83
85. exp “sensitivity and specificity”/
86. “reproducibility of results”/
87. (predict* adj3 (dement* or AD or alzheimer*)).ti,ab.
88. (identif* adj3 (dement* or AD or alzheimer*)).ti,ab.
89. (discriminat* adj3 (dement* or AD or alzheimer*)).ti,ab.
90. (distinguish* adj3 (dement* or AD or alzheimer*)).ti,ab.
91. (differenti* adj3 (dement* or AD or alzheimer*)).ti,ab.
92. diagnos*.ti.
93. di.fs.
94. sensitivit*.ab.
95. specificit*.ab.
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96. (ROC or “receiver operat*”).ab.
97. Area under curve/
98. (“Area under curve” or AUC).ab.
99. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.
100. sROC.ab.
101. accura*.ti,ab.
102. (likelihood adj3 (ratio* or function*)).ab.
103. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.
104. ((true or false) adj3 (positive* or negative*)).ab.
105. ((positive* or negative* or false or true) adj3 rate*).ti,ab
106. or/85-105
107. exp dementia/di
108. Cognition Disorders/di [Diagnosis]
109. Memory Disorders/di
110. or/107-109
111. *Neuropsychological Tests/
112. *Questionnaires/
113. Geriatric Assessment/mt
114. *Geriatric Assessment/
115. Neuropsychological Tests/mt, st
116. “neuropsychological test*”.ti,ab.
117. (neuropsychological adj (assess* or evaluat* or test*)).ti,ab
118. (neuropsychological adj (assess* or evaluat* or test* or exam*
or battery)).ti,ab
119. Self report/
120. self-assessment/ or diagnostic self evaluation/
121. Mass Screening/
122. early diagnosis/
123. or/111-122
124. 74 or 123
125. 110 and 124
126. 74 or 123
127. 84 and 106 and 126
128. 74 and 106
129. 125 or 127 or 128
130. (animals not (humans and animals)).sh.
131. 129 not 130
The concepts for this are:
A Specific neuropsychological tests (lines 1-73)
B General terms (both free text and MeSH) for tests/testing/
screening (lines 111-122)
COutcome: dementia diagnosis (unfocusedMeSHwith diagnos-
tic subheadings) (lines 107-109)
D Condition of interest: Dementia (general dementia terms both
free text and MeSH - exploded and unfocused) (75-83)
EMethodological filter: not used to limit all search (85-105)
The concept combinations are:
1. (A OR B) AND C
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2. (A OR B) AND D AND E
3. A AND E
Search strategy (MEDLINE OvidSP) run for specialised reg-
ister (ALOIS)
Search narrative: The search in Appendix 2 is largely based on
a single concept: the index test (IQCODE). This is a sensitive
approach to take. More complex and developed searches are run
each month for the dementia group
Every month the following strategy is run in MEDLINE (via
OvidSP). The results are screened based on a reading of title and
abstract. The full texts (where there is one) are then obtained and
a few key details about each study are extracted including Index
test/s and details of population and setting. For this review it was
expected that most studies would be identified through a search of
multiple sources based on one concept (the index test in question)
. However, we felt it was worth also searching ALOIS for any
studies which had evaluated the accuracy of IQCODE but had
not referred to it in the title or abstract of the reference
Appendix 4. Assessment of reporting quality - STARD checklist
Section and Topic
TITLE/ABSTRACT
KEYWORDS
1 Identify the article as a study of diagnostic accuracy (recommend MeSH heading ’sensi-
tivity and specificity’)
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic accuracy or
comparing accuracy between tests or across participant groups
METHODS
Participants 3 The study population: The inclusion and exclusion criteria, setting and locations where
data were collected
4 Participant recruitment: Was recruitment based on presenting symptoms, results from
previous tests, or the fact that the participants had received the index tests or the reference
standard?
5 Participant sampling: Was the study population a consecutive series of participants de-
fined by the selection criteria in item 3 and 4? If not, specify how participants were
further selected
6 Data collection: Was data collection planned before the index test and reference standard
were performed (prospective study) or after (retrospective study)?
Test methods 7 The reference standard and its rationale.
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(Continued)
8 Technical specifications of material and methods involved including how and when
measurements were taken, and/or cite references for index tests and reference standard
9 Definition of and rationale for the units, cut-offs and/or categories of the results of the
index tests and the reference standard
10 The number, training and expertise of the persons executing and reading the index tests
and the reference standard
11 Whether or not the readers of the index tests and reference standard were blind (masked)
to the results of the other test and describe any other clinical information available to
the readers
Statistical methods 12 Methods for calculating or comparing measures of diagnostic accuracy, and the statistical
methods used to quantify uncertainty (e.g. 95% confidence intervals)
13 Methods for calculating test reproducibility, if done.
RESULTS
Participants 14 When study was performed, including beginning and end dates of recruitment
15 Clinical and demographic characteristics of the study population (at least information
on age, gender, spectrum of presenting symptoms)
16 The number of participants satisfying the criteria for inclusion who did or did not
undergo the index tests and/or the reference standard; describe why participants failed
to undergo either test (a flow diagram is strongly recommended)
Test results 17 Time-interval between the index tests and the reference standard, and any treatment
administered in between
18 Distribution of severity of disease (define criteria) in those with the target condition;
other diagnoses in participants without the target condition
19 A cross tabulation of the results of the index tests (including indeterminate and missing
results) by the results of the reference standard; for continuous results, the distribution
of the test results by the results of the reference standard
20 Any adverse events from performing the index tests or the reference standard
Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% con-
fidence intervals)
22 How indeterminate results, missing data and outliers of the index tests were handled
23 Estimates of variability of diagnostic accuracy between subgroups of participants, readers
or centres, if done
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(Continued)
24 Estimates of test reproducibility, if done.
DISCUSSION 25 Discuss the clinical applicability of the study findings.
Appendix 5. Assessment of methodological quality table QUADAS-2 tool
DOMAIN PATIENT
SELECTION
INDEX TEST REFERENCE
STANDARD
FLOW AND TIMING
Description Describe methods of pa-
tient selection: Describe
included patients (prior
testing, presentation, in-
tended use of index test
and setting):
Describe the index test
and how it was con-
ducted and interpreted:
Describe the reference
standard and how it
was conducted and in-
terpreted:
Describe any patients
who did not receive the
index test(s) and/or ref-
erence standard or who
were excluded from the
2x2 table (refer to flow
diagram): Describe the
time interval and any in-
terventions between in-
dex test(s) and reference
standard:
Signalling questions
(yes/no/unclear)
Was a consecutive or ran-
dom sample of patients
enrolled?
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Is the reference standard
likely to correctly classify
the target condition?
Was there an appropri-
ate interval between in-
dex test(s) and reference
standard?
Was a case-control de-
sign avoided?
If a threshold was used,
was it pre-specified?
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Did all patients receive a
reference standard?
Did the study avoid in-
appropriate exclusions?
Did all patients receive
the same reference stan-
dard?
Were all patients in-
cluded in the analysis?
Risk of bias: High/low/
unclear
Could the selection of
patients have introduced
bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
Concerns regarding
applicability: High/low/
unclear
Are there concerns that
the included patients do
not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
Are there concerns that
the target condition as
defined by the reference
standard does not match
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(Continued)
question? the review question?
Appendix 6. Anchoring statements for quality assessment of IQCODE diagnostic studies
We provide some core anchoring statements for quality assessment of diagnostic test accuracy reviews of IQCODE in dementia. These
statements are designed for use with the QUADAS-2 tool and were derived during a two-day, multidisciplinary focus group.
During the focus group and the piloting/validation of this guidance, it was clear that certain issues were key to assessing quality, while
other issues were important to record but less important for assessing overall quality. To assist, we describe a system wherein certain
items can dominate. For these dominant items, if scored ’high risk’ then that section of the QUADAS-2 results table is likely to be
scored as high risk of bias regardless of other scores. For example, in dementia diagnostic test accuracy studies, ensuring that clinicians
performing dementia assessment are blinded to results of index test is fundamental. If this blinding was not present then the item on
reference standard should be scored ’high risk of bias’, regardless of the other contributory elements.
We have detailed how QUADAS2 has been operationlised for use with dementia reference stand rad studies below. In these descriptors
dominant items are labelled as ’hIgh risk’.
In assessing individual items, the score of unclear should only be given if there is genuine uncertainty. In these situations review authors
will contact the relevant study teams for additional information.
Anchoring statements to assist with assessment for risk of bias
Patient selection
Was a case-control or similar design avoided?
Designs similar to case control that may introduce bias are those designs where the study team deliberately increase or decrease the proportion
of patients with the target condition. For example, a population study may be enriched with extra dementia patients from a secondary care
setting. Such studies will be automatically labelled high risk of bias and will be assessed as a potential source of heterogeneity.
High risk of bias (in fact case-control studies will not be included in this review)
Was the sampling method appropriate?
Where sampling is used, the designs least likely to cause bias are consecutive sampling or random sampling. Sampling that is based on volunteers
or selecting participants from a clinic or research resource is prone to bias.
High risk of bias
Are exclusion criteria described and appropriate?
The study will be automatically graded as unclear if exclusions are not detailed (pending contact with study authors). Where exclusions are
detailed, the study will be graded as ’low risk’ if exclusions are felt to be appropriate by the review authors. Certain exclusions common
to many studies of dementia are: medical instability; terminal disease; alcohol/substance misuse; concomitant psychiatric diagnosis; other
neurodegenerative condition. For a community sample we would expect relatively few exclusions.
Post hoc exclusions will be labelled ’high risk’ of bias.
Low risk
Index test
Was IQCODE assessment performed without knowledge of clinical dementia diagnosis?
Terms such as ’blinded’ or ’independently and without knowledge of ’ are sufficient and full details of the blinding procedure are not required.
This item may be scored as ’low risk’ if explicitly described or if there is a clear temporal pattern to order of testing that precludes the need for
formal blinding i.e. all IQCODE assessments performed before dementia assessment.
High risk
Were IQCODE thresholds pre-specified?
For scales there is often a reference point (in units or categories) above which participants are classified as ’test positive’; this may be referred to
as threshold; clinical cut-off or dichotomisation point. A study is classified high risk of bias if the authors define the optimal cut-off post hoc
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based on their own study data. Certain papers may use an alternative methodology for analysis that does not use thresholds and these papers
should be classified as not applicable.
Low risk
Were sufficient data on IQCODE application given for the test to be repeated in an independent study?
Particular points of interest for IQCODE include method of administration (for example, self-completed questionnaire versus direct questioning
interview); nature of informant; language of assessment. If a novel form of IQCODE is used, details of the scale should be included or a
reference given to an appropriate descriptive text. Where IQCODE is used in a novel manner, for example, a translated questionnaire, there
should be evidence of validation.
Low risk
Reference standard
Is the assessment used for clinical diagnosis of dementia acceptable?
Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in DSM-IV and ICD-10. Criteria
specific to dementia subtypes include but are not limited to NINCDS-ADRDA criteria for Alzheimer’s dementia; McKeith criteria for Lewy
Body dementia; Lund criteria for frontotemporal dementias; and the NINDS-AIREN criteria for vascular dementia. Where the criteria used
for assessment is not familiar to the review authors and the Cochrane Dementia and Cognitive Improvement group this item should be classified
as ’high risk of bias’.
High risk
Was clinical assessment for dementia performed without knowledge of IQCODE?
Terms such as ’blinded’ or ’independent’ are sufficient and full details of the blinding procedure are not required. This may be scored as ’low
risk’ if explicitly described or if there is a clear temporal pattern to order of testing i.e. all dementia assessments performed before IQCODE
testing.
Informant rating scales and direct cognitive tests present certain problems. It is accepted that informant interview and cognitive testing is a
usual component of clinical assessment for dementia, however, specific use of the scale under review in the clinical dementia assessment should
be scored as high risk of bias. We have pre-specified that dementia diagnosis that explicitly uses IQCDODE will be classified as high risk of
bias.
High risk
Were sufficient data on dementia assessment method given for the assessment to be repeated in an independent study?
The criteria used for clinical assessment are discussed in another item. Particular points of interest for dementia assessment include the background
of the assessor, training/expertise of the assessor; additional information available to informdiagnosis (neuroimaging; neuropsychological testing).
Low risk
Patient flow
Was there an appropriate interval between IQCODE and clinical dementia assessment.
For a study looking at delayed verification there is no agreement on how long the interval should be between index test and first/last assessment
for dementia. An interval of less than six months is unlikely to be sufficient time for progression.
Low risk of bias
Did all patients get the same assessment for dementia regardless of IQCODE result?
There may be scenarios where only those patients who score ’test positive’ on IQCODE have a more detailed assessment. Where dementia
assessment (or other reference standard) differs between patients this should be classified as high risk of bias.
High risk of bias
Were all patients who received IQCODE assessment included in the final analysis?
If dropouts these should be accounted for; a maximum proportion of dropouts to remain low risk of bias has been specified as 20%.
Low risk of bias
Were missing IQCODE results or un-interpretable IQCODE results reported?
Where missing results are reported if there is substantial attrition (we have set an arbitrary value of 50% missing data) this should be scored
as high risk of bias.
Low risk of bias
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Applicability
Were included patients representative of the general population of interest?
The included patients should match the intended population as described in the review question. If not already specified in the review inclusion
criteria, setting will be particularly important - the review authors should consider population in terms of symptoms; pre-testing; potential
disease prevalence. Studies that use very selected patients or subgroups will be classified as poor applicability.
Was IQCODE performed consistently and in a manner similar to its use in clinical practice?
IQCODE studies will be judged against the original description of its use.
Was clinical diagnosis of dementia (or other reference standard) made in a manner similar to current clinical practice?
For many reviews, inclusion criteria and assessment for risk of bias will already have assessed the dementia diagnosis. For certain reviews
an applicability statement relating to reference standard may not be applicable. There is the possibility that a form of dementia assessment,
although valid, may diagnose a far larger proportion of patients with disease than usual clinical practice. In this instance the item should be
rated poor applicability.
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